( MENAFN - GlobeNewsWire - Nasdaq) NORWOOD, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the“Company”), announced today, that the Poster [#296] Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate , has been presented at American Society of Clinical Oncology (ASCO) Annual Conference by Dr.
Jian Zhang, Chief Physician (Oncology), Deputy Director of Administration, Clinical director of Phase 1 Centre, Fudan University Shanghai Cancer Center. The Phase 1 study, sponsored by CSPC Pharmaceuticals Group Limited in China, is evaluating the safety and tolerability of SYS6002 (CRB-701) in patients with advanced solid tumors who have failed or were intolerant to standard treatment. Patients were enrolled based on Nectin-4 staining with the exception of metastatic urothelial cancer (mUC) patients who were considered to be Nectin-4 positive.
The poster presents data as of the end of April 2024 from the dose escalation spanning 7 dose levels (0.2, 0.6, 1.
2, 1.8, 2.7, 3.
6 & 4.5 mg/Kg Q3W) and PK cohorts (2.7 and 3.
6 mg/Kg). “This latest data update provides additional insight following the initial observations from our partner CSPC's January 2024 data cut,” said Dr. Dominic Smethurst, Chief Medical Officer at Corbus.
“This larger set of patient data, along with additional confirmed responses, increases our confidence that CRB-701 is cl.
